Company Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease.
AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell’Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation.
The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019.
AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
| Country | United States |
| Founded | 1966 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Thomas Equels |
Contact Details
Address: 2117 SW Highway 484 Ocala, Florida 34473 United States | |
| Phone | 352 448 7797 |
| Website | aimimmuno.com |
Stock Details
| Ticker Symbol | AIM |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000109471 |
| CUSIP Number | 00901B105 |
| ISIN Number | US00901B1052 |
| Employer ID | 74-1668471 |
| SIC Code | 3812 |
Key Executives
| Name | Position |
|---|---|
| Thomas K. Equels Esq., J.D., M.S. | Executive Vice Chairman, Chief Executive Officer and President |
| Robert Dickey IV, M.B.A. | Chief Financial Officer |
| Peter W. Rodino III, Esq., J.D. | Chief Operating Officer, Executive Director of Governmental Relations, General Counsel and Secretary |
| Dr. Christopher McAleer Ph.D. | Scientific Officer |
| Ann Marie E. Coverly | Director of Administration and Human Resources and Deputy Investor Relations Coordinator |
| Dr. Ralph Christopher Cavalli Ph.D. | Vice President of QC and Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 8, 2013 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jul 2, 2013 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jul 1, 2013 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Jun 21, 2013 | 15-12G | Securities registration termination |
| Jun 19, 2013 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 19, 2013 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 19, 2013 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 19, 2013 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 19, 2013 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 13, 2013 | 10-Q | Quarterly Report |